+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 6 Actively Recruiting clinical trials

S

Actively Recruiting

Researchers are evaluating the safety and effects of a new drug called NNC0487-0111 in people with Heart Failure with preserved Ejection Fraction HFpEF or Heart Failure with mildly reduced Ejection Fraction HFmrEF who also have excess body weight. This study compares NNC0487-0111 against a placebo to determine if it is safe and effective for treating these heart conditions in people with obesity. The study is a randomized, controlled trial conducted by Novo Nordisk AS. Participants will receive either NNC0487-0111 or a placebo by subcutaneous injection once a week. The study drug dose may increase over time for those receiving NNC0487-0111. Treatment assignment is random, and the study includes a parallel design with two groups one receiving the experimental drug and one receiving placebo. The treatment period and monitoring last up to 165 weeks. During the study, participants will be monitored for heart failure events, cardiovascular death, hospital visits related to heart failure, and other major cardiovascular outcomes. They will complete questionnaires about their heart failure symptoms and quality of life. Kidney function will also be assessed in some participants. Safety and effectiveness will be evaluated throughout the study period, which can last over three years, with regular visits for injections and assessments.

Age: 18Years +All GendersPhase 3
838 locations
S

Actively Recruiting

Researchers are evaluating the effect of a triple therapy inhaler containing budesonide, glycopyrronium, and formoterol fumarate BGF MDI 32014.49.6 g compared to a dual therapy inhaler with glycopyrronium and formoterol fumarate GFF MDI 14.49.6 g on heart and lung outcomes in adults with chronic obstructive pulmonary disease COPD who have increased cardiopulmonary risk. This is a Phase III randomized, double-blind, parallel group, multi-center study designed to assess these treatments over an extended period. Participants will be randomly assigned to receive either the triple therapy BGF MDI or the dual therapy GFF MDI, each administered twice daily. The study aims to track the time to first severe cardiac or COPD event over up to three years. Both treatments involve pressurized inhalation suspensions delivered by metered-dose inhalers, and the study includes ongoing monitoring for up to three years during which various cardiopulmonary events and exacerbations will be recorded. During the study, participants will attend visits where their inhaler technique, lung function, blood markers such as eosinophil counts, and COPD assessment test scores will be evaluated. Researchers will measure outcomes including time to severe COPD exacerbations, cardiac events, cardiopulmonary death, and hospitalizations related to heart issues. Safety and efficacy will be closely monitored throughout the study duration, which may last up to three years, with regular follow-up assessments conducted in person or virtually as needed.

Age: 40Years - 80YearsAll GendersPhase 3
922 locations
P

Actively Recruiting

Atrial Septal Defect ASD is a type of congenital heart defect that may be closed without open-heart surgery. Traditionally, ASD closure was done surgically, but less invasive options like percutaneous transcatheter occluder devices have become available. This research aims to collect real-world clinical data and confirm the long-term safety and performance of the Lifetech Cera153 ASD Occluder, a device used to close ASD without surgery. The study also seeks to identify any previously unknown side effects of this device. Participants in this study will have received the Lifetech Cera153 ASD Occluder between January 2020 and December 2023, following instructions for use. The study is single-armed and observational, planned under the Regulation EU 2017745. Subjects will be followed up for two years after device implantation to track outcomes and safety. The enrollment period is expected to last about one year with a target of 139 participants. During the study, researchers will monitor procedural success six months after implantation and assess successful closure of the defect immediately after the procedure, at hospital discharge, and at 12 months. They will also track new onset arrhythmias requiring treatment, device or procedure-related adverse events and serious adverse events, as well as any deaths from the time of the procedure up to two years post-implantation. Participants must attend follow-up visits as part of the study, with all data collected and processed with their consent.

All AgesAll Genders
6 locations
C

Actively Recruiting

Researchers are investigating the best way to treat patients with multivessel coronary artery disease or left main narrowing who experience symptoms of acute ischemia, specifically those with non-ST-segment elevation acute coronary syndrome NSTE-ACS. This trial compares two treatments percutaneous coronary intervention PCI with drug-eluting stents and coronary artery bypass grafting CABG. The study aims to understand which method offers better outcomes for patients with complex coronary artery disease who need early invasive treatment. The study enrolls patients with multivessel disease or left main coronary artery disease, eligible for invasive treatment and with a Syntax Score below 33. Participants will be randomly assigned to receive either PCI, involving fractional flow reserve or iFR measurements and optimized stent implantation, or CABG surgery, performed with techniques including on-pump or off-pump methods. Treatment decisions involve a Heart Team consultation, and both approaches aim for complete revascularization. The trial will follow patients over time to compare outcomes. Participants will have follow-up visits including cardiac echocardiography and stress tests after hospitalization. The study will monitor major adverse cardiac and cerebral events MACCE, serious adverse events, procedural complications, cost effectiveness, and heart function over one year and beyond. Secondary outcomes include bleeding, atrial fibrillation, heart failure, rehospitalization, and quality of life. The total study duration extends until 2030, with primary outcome assessment at one year.

Age: 18Years +All GendersPhase Not Applicable
9 locations
E

Actively Recruiting

Researchers are evaluating whether catheter-based endovascular left atrial appendage occlusion can reduce the risk of ischemic stroke or systemic embolism in people with atrial fibrillation who remain at high stroke risk despite ongoing oral anticoagulation treatment. This multicenter, open-label, randomized controlled trial with blinded assessment aims to clarify the benefit of this intervention for stroke prevention in this population. Participants are randomly assigned to receive either the WATCHMAN device for left atrial appendage occlusion or standard medical care without this procedure. The WATCHMAN device is placed via a catheter to close off the left atrial appendage. Participants continue their oral anticoagulation as prescribed. The study expects an average follow-up of about 4 years, with the primary analysis conducted after 265 stroke or embolism events have occurred. During the study, participants undergo regular monitoring and assessments to track the occurrence of ischemic stroke, systemic embolism, and other cardiovascular events. Cognitive function is also evaluated using the Montreal Cognitive Assessment. Safety and mortality outcomes will be recorded throughout the trial duration. Participants are followed for the full study period estimated at around 4 years to gather comprehensive data on the interventions effects.

Age: 18Years +All GendersPhase Not Applicable
150 locations
Z

Actively Recruiting

Researchers are evaluating whether the drug zilebesiran can reduce major cardiovascular events such as cardiovascular death, nonfatal heart attacks, strokes, or heart failure in adults with hypertension that is not well controlled and who have either established cardiovascular disease or are at high risk for it. This is a phase 3, randomized, double-blind, placebo-controlled study that will continue until a targeted number of cardiovascular events have occurred. Participants will receive either 300 mg of zilebesiran or a placebo by subcutaneous injection every six months, in addition to their standard antihypertensive medications, which must include a thiazide, thiazide-like, or loop diuretic. The study involves two parallel groups one receiving the active drug and the other receiving placebo, both as add-on therapies to current treatment. During the trial, participants will be regularly monitored for cardiovascular outcomes over approximately five years. The main measurement is the time to the first occurrence of a composite endpoint including cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or heart failure events requiring hospitalization or urgent visits. Blood pressure changes at six months and other cardiovascular outcomes will also be assessed. Safety and effectiveness will be closely observed throughout the study period.

Age: 18Years +All GendersPhase 3
1190 locations